MicroRNAs in gynecological cancers: Small molecules with big implications
Gynecological cancers (GCs) are often diagnosed at advanced stages, limiting the efficacy
of available therapeutic options. Thus, there remains an urgent and unmet need for …
of available therapeutic options. Thus, there remains an urgent and unmet need for …
Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management
Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer,
contributing to the high mortality-to-incidence ratio. Management of the platinum-resistant …
contributing to the high mortality-to-incidence ratio. Management of the platinum-resistant …
Epigenetic basis of cancer health disparities: Looking beyond genetic differences
Despite efforts at various levels, racial health disparities still exist in cancer patients. These
inequalities in incidence and/or clinical outcome can only be explained by a multitude of …
inequalities in incidence and/or clinical outcome can only be explained by a multitude of …
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma
MA Stoff-Khalili, AA Rivera, JM Mathis… - Breast cancer research …, 2007 - Springer
Purpose Alternative and complementary therapeutic strategies need to be developed for
metastatic breast cancer. Virotherapy is a novel therapeutic approach for the treatment of …
metastatic breast cancer. Virotherapy is a novel therapeutic approach for the treatment of …
CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival
E Meng, B Long, P Sullivan, S McClellan… - Clinical & experimental …, 2012 - Springer
Cancer cells with the surface marker profile CD44+/CD24− have previously been described
to possess cancer stem cell-like properties. This manuscript evaluates those properties in …
to possess cancer stem cell-like properties. This manuscript evaluates those properties in …
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer
AS Case, RP Rocconi, JM Straughn Jr… - Obstetrics & …, 2006 - journals.lww.com
OBJECTIVE: To prospectively evaluate in a blinded fashion the accuracy of frozen section in
endometrial cancer. METHODS: Sixty patients with endometrial cancer or complex atypical …
endometrial cancer. METHODS: Sixty patients with endometrial cancer or complex atypical …
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b …
RP Rocconi, EA Grosen, SA Ghamande… - The lancet …, 2020 - thelancet.com
Background Gemogenovatucel-T is an autologous tumour cell vaccine manufactured from
harvested tumour tissue, which specifically reduces expression of furin and downstream …
harvested tumour tissue, which specifically reduces expression of furin and downstream …
[HTML][HTML] ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling
Objective Aldehyde dehydrogenase (ALDH) expressing cells have been characterized as
possessing stem cell-like properties. We evaluated ALDH+ ovarian cancer stem cell-like …
possessing stem cell-like properties. We evaluated ALDH+ ovarian cancer stem cell-like …
Factors associated with survival disparities between non-Hispanic Black and White patients with uterine cancer
CW Kucera, C Tian, CM Tarney, C Presti… - JAMA network …, 2023 - jamanetwork.com
Importance Disparities in survival exist between non-Hispanic Black (hereafter, Black) and
non-Hispanic White (hereafter, White) patients with uterine cancer. Objective To investigate …
non-Hispanic White (hereafter, White) patients with uterine cancer. Objective To investigate …
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer
KN Moore, TJ Herzog, S Lewin, RL Giuntoli… - Gynecologic …, 2007 - Elsevier
OBJECTIVE.: Cisplatin-based combination therapy produces higher response rates and
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …